| Company* (Country; Symbol) |
Company* (Country; Symbol) |
Type/Product Area | Terms/Details (Date) |
| I. MODIFIED AGREEMENTS | |||
| JUNE | |||
| MDRNA Inc. (MRNA) | RiboTask ApS (Denmark) | Agreement to eliminate all downstream financial consideration resulting from collaborations established between MDRNA and potential partners, which gives MDRNA full financial and transactional control of its UNA technology | The UNA platform is designed to provide drug-like properties to an siRNA; terms were not disclosed (6/19) |
| JULY | |||
| DermTech Inc.* | Stiefel Laboratories Inc.* | Feasibility study to identify genetic markers associated with acne | Financial terms were not disclosed (7/15) |
| OSI Pharmaceuticals Inc. (OSIP) | AVEO Pharmaceuticals Inc.* | Expanded drug discovery and translational research partnership developing therapies that target the underlying mechanisms of epithelial-mesenchymal transition in cancer and datasets of associated patient selection biomarkers | OSI will pay AVEO $20M at closing, $5M of which is an up-front cash payment and $15M for the purchase of additional equity in AVEO; OSI also will provide research funding over the next two years, and gains rights, beyond the original deal, to EMT targets and increased access to AVEO technology (7/21) |
|
Notes: * Private companies are indicated with an asterisk. Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
